NICE is citing "substantial uncertainty in the submitted data” as a reason not to recommend the drug, as well as a lack of "strong long-term evidence on remission with the treatment.”Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.